Literature DB >> 25027569

Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension.

Matthew Yan1, Holly Geyer2, Ruben Mesa2, Ehab Atallah3, Jeannie Callum1, Justyna Bartoszko1, Karen Yee4, Manjula Maganti5, Florence Wong1, Vikas Gupta6.   

Abstract

BACKGROUND: Portal hypertension has been reported to afflict 7% to 18% of patients with Philadelphia-negative MPNs, with complications of variceal bleeding and ascites. The clinical features and outcomes of these patients are unclear. PATIENTS AND METHODS: In this multicenter retrospective study, we evaluated the clinical features of 51 patients with MPNs complicated by PHTN.
RESULTS: The diagnosis of underlying MPN was most frequently PV (39%) and primary MF (35%), followed by post-PV MF (18%), ET (4%), and post-ET MF (4%). Frequency of Janus Kinase 2 V617F mutation appears as expected in the underlying MPN. Thrombosis within the splanchnic circulation was prevalent in patients with polycythemia compared with other MPNs (76% vs. 26%; P = .0007).
CONCLUSION: PV and MF patients have a greater incidence of PHTN in our population, with thrombosis contributing to PHTN development in PV patients. Patients with splanchnic circulation thrombosis are potential candidates for screening for PHTN. These data might be useful for developing screening strategies for early detection of PHTN in patients with MPN.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Essential thromobocythemia; JAK inhibitor; Myelofibrosis; Polycythemia vera; Thrombosis

Mesh:

Substances:

Year:  2014        PMID: 25027569      PMCID: PMC4361182          DOI: 10.1016/j.clml.2014.04.004

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  17 in total

1.  Ruxolitinib for myelofibrosis.

Authors:  Steffen Koschmieder; Adriane Koppelle; Hans Seifert
Journal:  N Engl J Med       Date:  2012-05-24       Impact factor: 91.245

Review 2.  Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.

Authors:  A M Vannucchi; E Antonioli; P Guglielmelli; A Pardanani; A Tefferi
Journal:  Leukemia       Date:  2008-05-22       Impact factor: 11.528

3.  Diagnosis and treatment of portal hypertension secondary to myeloproliferative disorders: a report of three cases.

Authors:  Gang Zhao; Zhi Yong Wu; Bin Zhang; Yong Wei Sun; Meng Luo
Journal:  J Dig Dis       Date:  2011-08       Impact factor: 2.325

4.  Portal hypertension secondary to myelofibrosis: a study of three cases.

Authors:  Alberto Alvarez-Larrán; Juan G Abraldes; Francisco Cervantes; Manuel Hernández-Guerra; Francesco Vizzutti; Rosa Miquel; Rosa Gilabert; Massimo Giusti; Juan Carlos Garcia-Pagan; Jaime Bosch
Journal:  Am J Gastroenterol       Date:  2005-10       Impact factor: 10.864

5.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

6.  Outcome of portal-systemic shunt surgery for portal hypertension associated with intrahepatic obstruction in patients with agnogenic myeloid metaplasia.

Authors:  A Tefferi; S M Barrett; M N Silverstein; D M Nagorney
Journal:  Am J Hematol       Date:  1994-08       Impact factor: 10.047

Review 7.  Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.

Authors:  Jasper H Smalberg; Lidia R Arends; Dominique C Valla; Jean-Jacques Kiladjian; Harry L A Janssen; Frank W G Leebeek
Journal:  Blood       Date:  2012-10-04       Impact factor: 22.113

8.  Endoscopic injection sclerotherapy for esophageal variceal hemorrhage in a patient with idiopathic myelofibrosis.

Authors:  M Takasaki; I Takahashi; M Takamatsu; S Yorimitsu; Y Yorimitsu; I Takeda; T Horimi
Journal:  J Gastroenterol       Date:  1996-04       Impact factor: 7.527

9.  Portal hypertension as presenting feature of a myeloproliferative disorder. Diagnosis and therapeutic dilemmas.

Authors:  E W Muller; J T De Wolf; E B Haagsma
Journal:  Scand J Gastroenterol Suppl       Date:  1993

10.  Portal hypertension in lymphoproliferative and myeloproliferative disorders: hemodynamic and histological correlations.

Authors:  A Dubois; M Dauzat; C Pignodel; G Pomier-Layrargues; C Marty-Double; F M Lopez; C Janbon
Journal:  Hepatology       Date:  1993-02       Impact factor: 17.425

View more
  7 in total

1.  Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension.

Authors:  Christopher R Reilly; Daria V Babushok; Karlyn Martin; Jerry L Spivak; Michael Streiff; Ranjeeta Bahirwani; Jeffrey Mondschein; Brady Stein; Alison Moliterno; Elizabeth O Hexner
Journal:  Am J Hematol       Date:  2017-07-26       Impact factor: 10.047

Review 2.  Interventional Management of Portal Hypertension in Cancer Patients.

Authors:  Max Kabolowsky; Lyndsey Nguyen; Brett E Fortune; Ernesto Santos; Sirish Kishore; Juan C Camacho
Journal:  Curr Oncol Rep       Date:  2022-08-12       Impact factor: 5.945

Review 3.  Splanchnic Vein Thrombosis in the Myeloproliferative Neoplasms.

Authors:  Imo J Akpan; Brady Lee Stein
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

4.  Clinical value of liver and spleen shear wave velocity in predicting the prognosis of patients with portal hypertension.

Authors:  Yan Zhang; Da-Feng Mao; Mei-Wu Zhang; Xiao-Xiang Fan
Journal:  World J Gastroenterol       Date:  2017-12-07       Impact factor: 5.742

5.  Pulmonary hypertension with massive megalosplenia: A case report.

Authors:  Tieci Yi; Wei Ma; Jianxing Qiu; Wenhui Ding
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

6.  Clinical characteristics of portal hypertension complicated by gastroesophageal varices in patients with myeloproliferative neoplasms.

Authors:  Jaejun Lee; Pil Soo Sung; Ki-Seong Eom; Hyun Yang; Soon Kyu Lee; Aung Hlaing Bwa; Angelo Lozada; Jeong Won Jang; Si Hyun Bae; Jong Young Choi; Seung Kew Yoon
Journal:  Clin Mol Hepatol       Date:  2019-11-26

7.  Characteristics of myeloproliferative neoplasm-associated portal hypertension and endoscopic management of variceal bleeding.

Authors:  Xiaoquan Huang; Ming Zhang; Yingjie Ai; Siyu Jiang; Mei Xiao; Lifen Wang; Yourong Jian; Yuzheng Zhuge; Chunqing Zhang; Shiyao Chen
Journal:  Ther Adv Chronic Dis       Date:  2022-09-22       Impact factor: 4.970

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.